 This is a multicentre, open labeled, prospective, randomized, controlled phase III study designed to assess the clinical performance of chemoembolization with LC Bead, loaded with irinotecan in combination with intravenous chemotherapy and bevacizumab versus intravenous chemotherapy in combination with bevacizumab in the treatment of unresectable liver metastases in patients with colorectal cancer. 